{
    "nct_id": "NCT05002127",
    "official_title": "A Phase 2/3 Study of Evorpacept (ALX148) in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)",
    "inclusion_criteria": "* HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)\n* Adequate Bone Marrow Function.\n* Adequate Renal & Liver Function.\n* Adequate Performance Status\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.\n* Prior treatment with any anti-CD47 or anti-SIRPÎ± agent.\n* Prior treatment with ramucirumab.",
    "miscellaneous_criteria": ""
}